Search

Your search keyword '"Campone, Mario"' showing total 208 results
208 results on '"Campone, Mario"'

1. p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

Author

Vanacker, Hélène, Treilleux, Isabelle, Schiffler, Camille, Bieche, Ivan, Campone, Mario, Patsouris, Anne, Arnedos, Monica, Cottu, Paul H., Jacquin, Jean-Philippe, Dalenc, Florence, Pinton, Antoine, Servant, Nicolas, Attignon, Valéry, Rouleau, Etienne, Morel, Alain, Legrand, François, Jimenez, Marta, Andre, Fabrice, and Bachelot, Thomas

Published
2024
Full Text
View/download PDF

3. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

Author

Giacchetti, Sylvie, Laas, Enora, Bachelot, Thomas, Lemonnier, Jérome, André, Fabrice, Cameron, David, Bliss, Judith, Chabaud, Sylvie, Hardy- Bessard, Anne-Claire, Lacroix-Triki, Magali, Canon, Jean-Luc, Debled, Marc, Campone, Mario, Cottu, Paul, Dalenc, Florence, Ballesta, Annabelle, Penault-Llorca, Frederique, Asselain, Bernard, Dumas, Elise, Reyal, Fabien, Gougis, Paul, Lévi, Francis, and Hamy, Anne-Sophie

Published
2024
Full Text
View/download PDF

5. Genomics to select treatment for patients with metastatic breast cancer

Author

Andre, Fabrice, Filleron, Thomas, Kamal, Maud, Mosele, Fernanda, Arnedos, Monica, Dalenc, Florence, Sablin, Marie-Paule, Campone, Mario, Bonnefoi, Hervé, Lefeuvre-Plesse, Claudia, Jacot, William, Coussy, Florence, Ferrero, Jean-Marc, Emile, George, Mouret-Reynier, Marie-Ange, Thery, Jean-Christophe, Isambert, Nicolas, Mege, Alice, Barthelemy, Philippe, You, Benoit, Hajjaji, Nawale, Lacroix, Ludovic, Rouleau, Etienne, Tran-Dien, Alicia, Boyault, Sandrine, Attignon, Valery, Gestraud, Pierre, Servant, Nicolas, Le Tourneau, Christophe, Cherif, Linda Larbi, Soubeyran, Isabelle, Montemurro, Filippo, Morel, Alain, Lusque, Amelie, Jimenez, Marta, Jacquet, Alexandra, Gonçalves, Anthony, Bachelot, Thomas, and Bieche, Ivan

Published
2022
Full Text
View/download PDF

6. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Author

Bardia, Aditya, Chandarlapaty, Sarat, Linden, Hannah M., Ulaner, Gary A., Gosselin, Alice, Cartot-Cotton, Sylvaine, Cohen, Patrick, Doroumian, Séverine, Paux, Gautier, Celanovic, Marina, Pelekanou, Vasiliki, Ming, Jeffrey E., Ternès, Nils, Bouaboula, Monsif, Lee, Joon Sang, Bauchet, Anne-Laure, and Campone, Mario

Published
2022
Full Text
View/download PDF

8. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program

Author

Cabel, Luc, Carton, Matthieu, Pistilli, Barbara, Dalenc, Florence, Vanlemnens, Laurence, Levy, Christelle, Jacot, William, Debled, Michel, Loeb, Agnes, Hennequin, Audrey, De la Motte Rouge, Thibault, Laborde, Lilian, Laurent, Carine, Chamorey, E., Parent, Damien, Petit, Thierry, Mouret-Reynier, Marie-Ange, Campone, Mario, Perrocheau, Geneviève, Labreveux, Claire, Bachelot, Thomas, Robain, Mathieu, and Lerebours, Florence

Published
2021
Full Text
View/download PDF

11. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Author

Bachelot, Thomas, Filleron, Thomas, Bieche, Ivan, Arnedos, Monica, Campone, Mario, Dalenc, Florence, and Coussy, Florence

Subjects
Chemotherapy -- Testing -- Comparative analysis, Cancer -- Chemotherapy, Breast cancer -- Drug therapy, Biological sciences, Health
Abstract

The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after six to eight cycles of chemotherapy. Patients (n = 199) were randomized to either durvalumab (10 mg kg.sup.-1 every 2 weeks) or maintenance chemotherapy. In the overall population, durvalumab did not improve progression-free survival (adjusted hazard ratio (HR): 1.40, 95% confidence interval (CI): 1.00-1.96; P = 0.047) or overall survival (OS; adjusted HR: 0.84, 95% CI: 0.54-1.29; P = 0.423). In an exploratory subgroup analysis, durvalumab improved OS in patients with triple-negative breast cancer (TNBC; n = 82; HR: 0.54, 95% CI: 0.30-0.97, P = 0.0377). Exploratory analysis showed that the HR of death was 0.37 (95% CI: 0.12-1.13) for patients with PD-L1.sup.+ TNBC (n = 32) and 0.49 (95% CI: 0.18-1.34) for those with PD-L1.sup.- TNBC (n = 29). In patients with TNBC, exploratory analyses showed that the HR for durvalumab efficacy (OS) was 0.18 (95% CI: 0.05-0.71; log-rank test, P = 0.0059) in patients with CD274 gain/amplification (n = 23) and 1.12 (95% CI: 0.42-2.99; log-rank test, P = 0.8139) in patients with CD274 normal/loss (n = 32). Tumor infiltration by lymphocytes (CD8, FoxP3 and CD103 expressions) and homologous recombination deficiency did not predict sensitivity to durvalumab in exploratory analyses. This latter finding should be interpreted with caution since only one patient presented a germline BRCA mutation. The present study provides a rationale to evaluate single-agent durvalumab in maintenance therapy in patients with TNBC. Exploratory analyses identified CD274 amplification as a potential biomarker of sensitivity. Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease. Exploratory analyses from the phase 2 randomized SAFIR02-IMMUNO trial identify biomarkers associated with improved outcomes to durvalumab as compared to maintenance chemotherapy in patients with triple-negative breast cancer., Author(s): Thomas Bachelot [sup.1] , Thomas Filleron [sup.2] , Ivan Bieche [sup.3] , Monica Arnedos [sup.4] , Mario Campone [sup.5] , Florence Dalenc [sup.6] , Florence Coussy [sup.7] , Marie-Paule [...]

Published
2021
Full Text
View/download PDF

12. Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.

Author

Zhou, Ke, Robert, Marie, Seegers, Valérie, Blanc-Lapierre, Audrey, Savouroux, Stéphane, Bigot, Frédéric, Frenel, Jean-Sébastien, Campone, Mario, Conroy, Thierry, Penault-Llorca, Frédérique, Raoul, Jean-Luc, and Bellanger, Martine M.

Subjects
TREATMENT delay (Medicine), COVID-19 pandemic, DELAYED diagnosis, CANCER patients, BREAST cancer, GAMMA distributions
Abstract

Background: Longer times between diagnosis and treatments of cancer patients have been estimated as effects of the COVID-19 pandemic. However, relatively few studies attempted to estimate actual delay to treatment at the patient level. Objective: To assess changes in delays to first treatment and surgery among newly diagnosed patients with localized breast cancer (BC) during the COVID-19 pandemic. Methods: We used data from the PAPESCO-19 multicenter cohort study, which included patients from 4 French comprehensive cancer centers. We measured the delay to first treatment as the number of days between diagnosis and the first treatment regardless of whether this was neoadjuvant chemotherapy or surgery. COVID-19 pandemic exposure was estimated with a composite index that considered both the severity of the pandemic and the level of lockdown restrictions. We ran generalized linear models with a log link function and a gamma distribution to model the association between delay and the pandemic. Results: Of the 187 patients included in the analysis, the median delay to first treatment was 42 (IQR:32–54) days for patients diagnosed before and after the start of the 1st lockdown (N = 99 and 88, respectively). After adjusting for age and centers of inclusion, a higher composite pandemic index (> = 50 V.S. <50) had only a small, non-significant effect on times to treatment. Longer delays were associated with factors other than the COVID-19 pandemic. Conclusion: We found evidence of no direct impact of the pandemic on the actual delay to treatment among patients with localized BC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study

Author

Callens, Céline, Driouch, Keltouma, Boulai, Anaïs, Tariq, Zakia, Comte, Aurélie, Berger, Frédérique, Belin, Lisa, Bièche, Ivan, Servois, Vincent, Legoix, Patricia, Bernard, Virginie, Baulande, Sylvain, Chemlali, Walid, Bidard, François-Clément, Fourchotte, Virginie, Salomon, Anne Vincent-, Brain, Etienne, Lidereau, Rosette, Bachelot, Thomas, Saghatchian, Mahasti, Campone, Mario, Giacchetti, Sylvie, Zafrani, Brigitte Sigal, and Cottu, Paul

Published
2021
Full Text
View/download PDF

17. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

Author

Frank, Sophie, Carton, Matthieu, Dubot, Coraline, Campone, Mario, Pistilli, Barbara, Dalenc, Florence, Mailliez, Audrey, Levy, Christelle, D’Hondt, Véronique, Debled, Marc, Vermeulin, Thomas, Coudert, Bruno, Perrin, Christophe, Gonçalves, Anthony, Uwer, Lionel, Ferrero, Jean-Marc, Eymard, Jean-Christophe, Petit, Thierry, Mouret-Reynier, Marie-Ange, Patsouris, Anne, Guesmia, Tahar, Bachelot, Thomas, Robain, Mathieu, and Cottu, Paul

Published
2020
Full Text
View/download PDF

18. Oncological care organisation during COVID-19 outbreak

Author

Onesti, Concetta Elisa, Rugo, Hope S., Generali, Daniele, Peeters, Marc, Zaman, Khalil, Wildiers, Hans, Harbeck, Nadia, Martin, Miguel, Cristofanilli, Massimo, Cortes, Javier, Tjan-Heijnen, Vivianne, Hurvitz, Sara A., Berchem, Guy, Tagliamento, Marco, Campone, Mario, Bartsch, Rupert, De Placido, Sabino, Puglisi, Fabio, Rottey, Sylvie, Müller, Volkmar, Ruhstaller, Thomas, Machiels, Jean-Pascal, Conte, PierFranco, Awada, Ahmad, and Jerusalem, Guy

Published
2020
Full Text
View/download PDF

21. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Author

Darlix, Amélie, Louvel, Guillaume, Fraisse, Julien, Jacot, William, Brain, Etienne, Debled, Marc, Mouret-Reynier, Marie Ange, Goncalves, Anthony, Dalenc, Florence, Delaloge, Suzette, Campone, Mario, Augereau, Paule, Ferrero, Jean Marc, Levy, Christelle, Fumet, Jean-David, Lecouillard, Isabelle, Cottu, Paul, Petit, Thierry, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Dieras, Véronique, Robain, Mathieu, Chevrot, Michaël, Pasquier, David, and Bachelot, Thomas

Published
2019
Full Text
View/download PDF

22. A regionally based precision medicine implementation initiative in North Africa:The PerMediNA consortium

Author

benider, Abdellatif, El-hamouchi, Adil, Sonia, AIT YOUNES, Kahla, Alia Ben, Abdelmalik, AMIMER, Zine, AMIR, charif, Jaballah, Amira, Louiza, Amira, GIHBID, Amina, Achouak, BACHIR, Djihad, BELABDI, Said, BELHADEF, Rafika, BELNOUI, Ayed, Belarbi, Nadia, Benchakroune, Nadia, Benchakroun, Meriem, BENINAL, Radja, BENKALI, Asma, BENSIHAMDI, Hichem, BENYOUCEF, Thouraya, BENDIMRED, Nadir, Bensouf, Rafika, BENNOUI, Yosra, Berrazegua, Latefa, Biskri, Saida, BOUAOUNI, Meriem, BOUANIKA, Abderezzak, Bouamra, Hanen, Bouaziz, Zohra, Boudinar Fatma, Sabrina, Bouhara, Nadir, Boussouf, Saber, Boutayeb, Adda, BOUNEDJAR, Omar, Chabati, Cherine, Charfeddine, Dalia, Chilla, Mehemmai, Chiraz, Bouabid, Cyrine, Souad, Dahnane, Soraya, DIAB, Adlane, Dib Hocine, Wider, Dorra, Fawzi, DERRAR, Amina, ELKEBOUB, Hicham, EL ATTAR, Elmostafa, EL FAHIME, Djazia, ELHADEF, Fehri, Emna, Hakkou, Farid, Hadjam, Farida, Mamboisse, Fanny, Widad, GAIS, Merzak, GHARNAOUT, Nidhal, Guessoum Amir, Farida, HADJAM, SAHRAOUI, HADJ, Rachdi, Haifa, Yaiche, Hamza, Leila, HANNACHI, Mahfouf, Hassan, Bouguerra, Hend, Attar, Hicham El, Hassine, Hichem Ben, Filali, Houda, Harmak, Houda, Kanaane, Houda, Benamri, Ichrak, Alami, Imane El, Reda, KASSA, Bendahhou, Karima, Errafii, Khaoula, Bairi, Khalid El, Wafaa, Khaali, Mehdi, KARKOURI, Maria, Kabbage, Wafa, Kammoun, Houda, Kanaane, Reda, Kassa, Narimane, LAOUAR, Biskri, Latefa, Amira, Louiza, Marie, Louise, Chevalier, Charion, Nabila, MALOUM, Monot, Marc, Saadi, Mariem, Campone, Mario, Mrad, Mehdi, KARKOURI, MEHDI, Mohamed, MELIZI, Saadi, Meriem, CHAHER, Meriem, Ardhaoui, Monia, TALEB, Mourad, Jmiaa, Nadia Ben, Benchakroun, Nadia, Hadhri, Najet, SALHI, Nawel, Taoufiq, Nezha, Jandoubi, Nouha, Wahiba, OUAHIOUNE, Salima, OULDSLIMANE, BELNOUI, Rafika, Louiza, Rahman Amira, Benkhalifa, Rym, Boutaib, Saber, Boutayeb, Saber, Menif, Samia, OULDSLIMANE, Salima, Valcke, Samuel, Assia, SLIMANI, Nasr, Sonia Ben, Maatoug, Sonia, Younes, Sonia Ait, BENCHEHIDA, Souad, BEKOUACI, Souad, Sahraoui, Souha, Hassiba, Tali Maamar, Soraya, Talha, Mourad, TALEB, Fella, TERKMANI, Soraya, TALHA, Wassila, TOUISI, Kammoun, Wafa, OUAHIOUNE, Wahiba, Berrazegua, Yosra, Amel, ZEMMOUR, Sarah, ZEROUAL, AMIR, Zine Charif, Zouafi, Zineb, Hamdi, Yosr, Boujemaa, Maroua, Ben Aissa-Haj, Jihenne, Radouani, Fouzia, Khyatti, Meriem, Mighri, Najah, Hannachi, Mariem, Ghedira, Kais, Souiai, Oussema, Hkimi, Chaima, Kammoun, Mohamed Selim, Mejri, Nesrine, Bouaziz, Hanen, Beloufa, Mohamed Amine, Charoute, Hicham, Barakat, Abdelhamid, Najjar, Imène, Taniguchi, Hiroaki, Pietrosemoli, Natalia, Dellagi, Koussay, Abdelhak, Sonia, Boubaker, Mohamed Samir, Chica, Claudia, and Rouleau, Etienne

Published
2024
Full Text
View/download PDF

23. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

25. Genomic characterization of metastatic breast cancers

Author

Bertucci, François, Ng, Charlotte K. Y., Patsouris, Anne, Droin, Nathalie, Piscuoglio, Salvatore, Carbuccia, Nadine, Soria, Jean Charles, Dien, Alicia Tran, Adnani, Yahia, Kamal, Maud, Garnier, Séverine, Meurice, Guillaume, Jimenez, Marta, Dogan, Semih, Verret, Benjamin, Chaffanet, Max, Bachelot, Thomas, Campone, Mario, Lefeuvre, Claudia, Bonnefoi, Herve, Dalenc, Florence, Jacquet, Alexandra, De Filippo, Maria R., Babbar, Naveen, Birnbaum, Daniel, Filleron, Thomas, Le Tourneau, Christophe, and André, Fabrice

Published
2019
Full Text
View/download PDF

26. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

Author

Onesti, Concetta Elisa, Tagliamento, Marco, Curigliano, Giuseppe, Harbeck, Nadia, Bartsch, Rupert, Wildiers, Hans, Tjan-Heijnen, Vivianne, Martin, Miguel, Rottey, Sylvie, Generali, Daniele, Campone, Mario, Cristofanilli, Massimo, Pusztai, Lajos, Peeters, Marc, Berchem, Guy, Cortes, Javier, Ruhstaller, Thomas, Ciruelos, Eva, Rugo, Hope S., and Jerusalem, Guy

Published
2021
Full Text
View/download PDF

29. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment

Author

Lohard, Steven, Bourgeois, Nathalie, Maillet, Laurent, Gautier, Fabien, Fétiveau, Aurélie, Lasla, Hamza, Nguyen, Frédérique, Vuillier, Céline, Dumont, Alison, Moreau-Aubry, Agnès, Frapin, Morgane, David, Laurent, Loussouarn, Delphine, Kerdraon, Olivier, Campone, Mario, Jézéquel, Pascal, Juin, Philippe P., and Barillé-Nion, Sophie

Published
2020
Full Text
View/download PDF

33. COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19).

Author

Seegers, Valérie, Rousseau, Guillaume, Zhou, Ke, Blanc-Lapierre, Audrey, Bigot, Frédéric, Mahammedi, Hakim, Lambert, Aurélien, Moreau-Bachelard, Camille, Campone, Mario, Conroy, Thierry, Penault-Llorca, Frédérique, Bellanger, Martine M., and Raoul, Jean-Luc

Subjects
RESEARCH, COVID-19, IMMUNIZATION, COVID-19 vaccines, AGE distribution, CANCER chemotherapy, CANCER patients, SEX distribution, GASTROINTESTINAL tumors, RISK assessment, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, RADIOTHERAPY, COVID-19 pandemic, LONGITUDINAL method, FEMALE reproductive organ tumors, IMMUNOTHERAPY, DISEASE complications
Abstract

Simple Summary: In two cohorts of vaccinated cancer patients and healthcare workers, 5% had COVID-19 infection after vaccination. These infections occurred more frequently in younger cancer patients with gastrointestinal cancer, gynecological or breast cancer, or a localized cancer and in patients receiving chemotherapy or targeted therapy when vaccinated. In both cohorts, these breakthrough infections occurred early after initiation of vaccination (Alpha SARS-CoV-2 variant) or several months after the end of vaccination (Omicron SARS-CoV-2 variant). In both cohorts these COVID-19 cases in vaccinated individuals were not severe, with only four cancer patients requiring oxygen therapy. In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; n = 935) vaccinated against COVID-19, we noticed the following: i/after vaccination, 4.4% of HCWs and 5.8% of CP were infected; ii/no characteristic was associated with post-vaccine COVID-19 infections among HCWs; iii/CP who developed infections were younger, more frequently women (NS), more frequently had gastrointestinal, gynecological, or breast cancer and a localized cancer stage; iv/CP vaccinated while receiving chemotherapy or targeted therapy had (NS) more breakthrough infections after vaccination than those vaccinated after these treatments; the opposite was noted with radiotherapy, immunotherapy, or hormonotherapy; v/most COVID-19 infections occurred either during the Alpha wave (11/41 HCW, 20/49 CP), early after the first vaccination campaign started, or during the Omicron wave (21/41 HCW, 20/49 CP), more than 3 months after the second dose; vi/risk of infection was not associated with values of antibody titers; vii/the outcome of these COVID-19 infections after vaccination was not severe in all cases. To conclude, around 5% of our CPs or HCWs developed a COVID-19 infection despite previous vaccination. The outcome of these infections was not severe. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co‐deleted anaplastic gliomas

Author

Bielle, Franck, Ducray, François, Mokhtari, Karima, Dehais, Caroline, Adle‐Biassette, Homa, Carpentier, Catherine, Chanut, Anaïs, Polivka, Marc, Poggioli, Sylvie, Rosenberg, Shai, Giry, Marine, Marie, Yannick, Duyckaerts, Charles, Sanson, Marc, Figarella‐Branger, Dominique, Idbaih, Ahmed, Desenclos, Christine, Sevestre, Henri, Menei, Philippe, Rousseau, Audrey, Godard, Joel, Viennet, Gabriel, Carpentier, Antoine, Eimer, Sandrine, Loiseau, Hugues, Dam‐Hieu, Phong, Quintin‐Roué, Isabelle, Guillamo, Jean‐Sebastien, Lechapt‐Zalcman, Emmanuelle, Kemeny, Jean‐Louis, Khallil, Toufik, Cazals‐Hatem, Dominique, Faillot, Thierry, Carpiuc, Ioana, Richard, Pomone, Le Guerinel, Caroline, Gaultier, Claude, Tortel, Marie‐Christine, Aubriot‐Lorton, Marie‐Hélène, Ghiringhelli, François, Adam, Clovis, Parker, Fabrice, Maurage, Claude‐Alain, Ramirez, Carole, Marcel Gueye, Edouard, Labrousse, François, Jouvet, Anne, Chinot, Olivier, Bauchet, Luc, Rigau, Valérie, Beauchesne, Patrick, Gauchotte, Guillaume, Campone, Mario, Loussouarn, Delphine, Fontaine, Denys, Vandenbos, Fanny, Blechet, Claire, Fesneau, Mélanie, Yves Delattre, Jean, Elouadhani‐Hamdi, Selma, Ricard, Damien, Larrieu‐Ciron, Delphine, Levillain, Pierre‐Marie, Colin, Philippe, Diebold, Marie‐Danièle, Chiforeanu, Danchristian, Vauléon, Elodie, Langlois, Olivier, Laquerrière, Annie, Motsuo Fotso, Marie Janette, Peocʼh, Michel, Andraud, Marie, Runavot, Gwenaelle, Chenard, Marie‐Pierre, Noel, Georges, Gaillard, Stéphane, Villa, Chiara, Desse, Nicolas, Cohen‐Moyal, Elisabeth, Uro‐Coste, Emmanuelle, and Dhermain, Frédéric

Published
2017
Full Text
View/download PDF

41. Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer

Author

Chatzipli, Aikaterini, Bonnefoi, Hervé, Macgrogan, Gaetan, Sentis, Julie, Cameron, David, Poncet, Coralie, Abadie-lacourtoisie, Sophie, Bodmer, Alexandre, Brain, Etienne, Cufer, Tanja, Campone, Mario, Luporsi, Elisabeth, Moldovan, Cristian, Petit, Thierry, Piccart, Martine, Priou, Franck, Senkus, Elsbieta, Zaman, Khalil, and Iggo, Richard

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Neoplasm, Residual, Receptor, ErbB-2, medicine.medical_treatment, Estrogen receptor, Antineoplastic Agents, Breast Neoplasms, Drug resistance, Disease, Article, CDH1, Cyclin D1, Breast cancer, Gene Frequency, Internal medicine, Humans, Medicine, Gene Regulatory Networks, Chemotherapy, biology, business.industry, Gene Amplification, GATA3, Sequence Analysis, DNA, medicine.disease, Neoadjuvant Therapy, Treatment Outcome, Receptors, Estrogen, Mutation, biology.protein, Female, business
Abstract

Background Treatment of patients with residual disease after neoadjuvant chemotherapy for breast cancer is an unmet clinical need. We hypothesised that tumour subclones showing expansion in residual disease after chemotherapy would contain mutations conferring drug resistance. Methods We studied oestrogen receptor and/or progesterone receptor-positive, HER2-negative tumours from 42 patients in the EORTC 10994/BIG 00-01 trial who failed to achieve a pathological complete response. Genes commonly mutated in breast cancer were sequenced in pre and post-treatment samples. Results Oncogenic driver mutations were commonest in PIK3CA (38% of tumours), GATA3 (29%), CDH1 (17%), TP53 (17%) and CBFB (12%); and amplification was commonest for CCND1 (26% of tumours) and FGFR1 (26%). The variant allele fraction frequently changed after treatment, indicating that subclones had expanded and contracted, but there were changes in both directions for all of the commonly mutated genes. Conclusions We found no evidence that expansion of clones containing recurrent oncogenic driver mutations is responsible for resistance to neoadjuvant chemotherapy. The persistence of classic oncogenic mutations in pathways for which targeted therapies are now available highlights their importance as drug targets in patients who have failed chemotherapy but provides no support for a direct role of driver oncogenes in resistance to chemotherapy. CLINICALTRIALS.GOV: EORTC 10994/BIG 1-00 Trial registration number NCT00017095.

Published
2021

45. COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).

Author

Seegers, Valérie, Rousseau, Guillaume, Zhou, Ke, Blanc-Lapierre, Audrey, Bigot, Frédéric, Mahammedi, Hakim, Lambert, Aurélien, Moreau-Bachelard, Camille, Campone, Mario, Conroy, Thierry, Penault-Llorca, Frédérique, Boisdron-Celle, Michèle, Bellanger, Martine, and Raoul, Jean-Luc

Subjects
CANCER patient psychology, COVID-19, IMMUNIZATION, EVALUATION of human services programs, SPECIALTY hospitals, GENETIC mutation, COVID-19 vaccines, MEDICAL personnel, MEDICAL protocols, CANCER treatment, PSYCHOSOCIAL factors, MESSENGER RNA, DESCRIPTIVE statistics, HOSPITAL care, LONGITUDINAL method
Abstract

Simple Summary: Vaccination against COVID-19 was a major weapon against current epidemics. In a multicenter cohort study conducted in cancer patients (CP) and health care workers (HCW) we demonstrated that: (i) vaccination was well accepted in both cohorts; (ii) the seropositivity rate was high after the first and second injections among HCW and among CP this was only after the second injection; (iii) similar patterns in antibody response followed the second dose; in both groups, antibody levels waned 3 months after the second dose. Overall, two-dose COVID-19 vaccination was effective in both populations studied, but could not totally prevent a few vaccine breakthrough infections, owing to the continuously emerging novel variants. In this prospective, real-life cohort study, we followed 523 cancer patients (CP) and 579 healthcare workers (HCW) from two cancer centers to evaluate the biological and clinical results of the COVID-19 vaccination campaign. Seventy percent of the CP and 90% of the HCW received an mRNA vaccine or the AZD1222 vaccine. Seropositivity was high after the first vaccine among HCW and poor among CP. The second dose resulted in almost 100% seropositivity in both cohorts. Antibody response was higher after the second injection than the first in both populations. Despite at least two doses, 8 CP (1.5%) and 14 HCW (2.4%) were infected, corresponding either to a weak level of antibody or a new strain of virus (particularly the Omicron variant of concern). Sixteen CP and three HCW were hospitalized but none of them died from COVID-19. To conclude, this study showed that two doses of COVID-19 vaccines were crucially necessary to attain sufficient seropositivity. However, the post-vaccination antibody level declines in individuals from the two cohorts and could not totally prevent new SARS-CoV-2 infections. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life.

Author

Ke Zhou, Bellanger, Martine, Le Lann, Sophie, Robert, Marie, Frenel, Jean-Sebastien, and Campone, Mario

Subjects
PATIENT reported outcome measures, BREAST cancer, QUALITY of life, TREATMENT effectiveness, RADIOTHERAPY, BREAST cancer surgery
Abstract

Purpose: Patient-reported outcomes (PROs) have been widely used to measure breast cancer (BC) treatment outcomes. However, evidence is still limited on using routinely PROs to personalize treatment decision-making, including or not chemotherapy, targeted therapy, and radiotherapy. Using patient baseline PRO scores, we aimed to use PROs before treatment initiation to predict improvement or decline in health-related quality of life (HRQoL) due to treatment that they receive. Methods: In two French cancer sites, women with non-metastatic BC completed the EORTC QLQ-C30 and QLQ-BR23 and BREAST-Q questionnaires to assess their PROs at baseline and again at 6 months. The outcome measured was post-operative change in PROs with minimal important difference for QLQ-C30 domains. We performed multivariate ordinal logistic regression to estimate the incremental probability of post-operative PRO improvements and deteriorations depending upon treatment options and baseline HRQoL. Results: One hundred twenty-seven women completed questionnaires. Chemotherapy had significant negative impacts on Global health status (GHS) and on physical and social functioning. Chemotherapy and radiotherapy increased patient fatigue scores after adjusting for clinical factors (p< 0.01 and p< 0.05, respectively). The incremental probability of GHS deteriorations for chemotherapy was +0.3, +0.5, and +0.34 for patients with baseline GHS scores of 40, 70, and 100, respectively. This showed that different pre-treatment PROs might predict differential effects of chemotherapy on women change in HRQoL. Conclusion: Patients with different baseline PRO scores may experience dissimilar impacts from BC treatments on post-operative PROs in terms of improvements and deteriorations. Oncologists might decide to adapt the treatment option based on a given level of the negative impact. Future studies should concentrate on incorporating this information into routine clinical decision-making strategies to optimize the treatment benefit for patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Author

Farmer, Pierre, Bonnefoi, Herve, Anderle, Pascale, Cameron, David, Wirapati, Pratyakasha, Becette, Veronique, Andre, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaetan, Petit, Thierry, Jassem, Jacek, Bibeau, Frederic, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard, and Delorenzi, Mauro

Subjects
Breast cancer -- Drug therapy, Breast cancer -- Research, Neoadjuvant therapy -- Health aspects, Drug resistance -- Genetic aspects, Drug resistance -- Research, Genes -- Physiological aspects, Genes -- Research
Abstract

To better understand the relationship between tumor-host interactions and the efficacy of chemotherapy, we have developed an analytical approach to quantify several biological processes observed in gene expression data sets. We tested the approach on tumor biopsies from individuals with estrogen receptor-negative breast cancer treated with chemotherapy. We report that increased stromal gene expression predicts resistance to preoperative chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in subjects in the EORTC 10994/131G 00-01 trial. The predictive value of the stromal signature was successfully validated in two independent cohorts of subjects who received chemotherapy but not in an untreated control group, indicating that the signature is predictive rather than prognostic. The genes in the signature are expressed in reactive stroma, according to reanalysis of data from microdissected breast tumor samples. These findings identify a previously undescribed resistance mechanism to FEC treatment and suggest that antistromal agents may offer new ways to overcome resistance to chemotherapy., &&&& Preoperative chemotherapy leads to the disappearance of the primary tumor (pathological complete response; pCR) in less than 10% of estrogen receptor-positive breast tumors and in 20-30% of estrogen receptor-negative [...]

Published
2009

50. Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.

Author

Domergue, Camille, Martin, Elodie, Lemarié, Camille, Jézéquel, Pascal, Frenel, Jean-Sebastien, Augereau, Paule, Campone, Mario, and Patsouris, Anne

Subjects
BREAST cancer prognosis, ONCOGENES, CANCER chemotherapy, MULTIVARIATE analysis, METASTASIS, TUMOR classification, COMBINED modality therapy, PROGRESSION-free survival, ODDS ratio, BREAST tumors, LONGITUDINAL method
Abstract

Simple Summary: HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer (BC) is an emerging subtype of BC with promising results with antibody drug conjugate (ADC) in the metastatic setting. In the early setting, few data have been reported regarding the predictive and prognostic impact of HER2-low status in triple-negative BC (TNBC). Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. Methods: We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS). Results: 437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, p = 0.284) in either univariate analysis or multivariate analysis adjusted for TNM classification and grade (odds ratio [OR] = 0.70, confidence interval [CI] 95% 0.45–1.08). With a median follow-up of 72.9 months, no significant survival differences were observed between patients with HER2-low tumours vs. patients with HER2-0 tumours in terms of I-DFS (p = 0.487) and OS (p = 0.329). Conclusions: In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results